ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences
India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
- Market Cap ₹ 49.8 Cr.
- Current Price ₹ 38.1
- High / Low ₹ 49.7 / 17.6
- Stock P/E
- Book Value ₹ 35.6
- Dividend Yield 0.00 %
- ROCE -2.32 %
- ROE -16.5 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.07 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.66% over past five years.
- Company has a low return on equity of -14.4% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 267 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 55 | 67 | 75 | 121 | 126 | 154 | 354 | 220 | 145 | 93 | 93 | 78 | |
| Sales growth | +7% | +49% | +22% | +12% | +61% | +4% | +129% | -38% | -34% | -36% | +0% | -16% | |
| 34 | 50 | 60 | 68 | 110 | 114 | 140 | 286 | 205 | 135 | 94 | 90 | 80 | |
| Operating Profit | 3 | 5 | 6 | 7 | 12 | 12 | 14 | 68 | 15 | 10 | -1 | 3 | -2 |
| OPM % | 8% | 9% | 10% | 10% | 10% | 10% | 9% | 19% | 7% | 7% | -1.6% | 2.8% | -2.9% |
| 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 10 | -1 | 2 | -1 | 1 | |
| Interest | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 9 | 12 | 11 | 9 | 8 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 9 | 8 | 7 | 6 | 6 |
| Profit before tax | 1 | 2 | 4 | 5 | 8 | 8 | 10 | 54 | 3 | -11 | -16 | -13 | -16 |
| Tax % | 32% | 25% | 26% | 25% | 30% | 28% | 31% | 25% | 110% | -5% | -21% | -15% | |
| 0 | 2 | 3 | 4 | 6 | 6 | 7 | 40 | -0 | -10 | -12 | -11 | -12 | |
| EPS in Rs | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 | -9.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 0% | 0% | 0% | 0% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -25% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -39% |
| 3 Years: | -17% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -14% |
| Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 5 | 5 | 5 | 10 | 13 | 13 | 13 | 13 | 13 | |
| Reserves | -1 | 1 | 4 | 18 | 24 | 29 | 73 | 73 | 63 | 51 | 40 | 33 | |
| 10 | 12 | 14 | 17 | 22 | 21 | 77 | 71 | 73 | 83 | 79 | 86 | ||
| 13 | 19 | 25 | 28 | 30 | 39 | 130 | 119 | 92 | 82 | 78 | 84 | ||
| Total Liabilities | 26 | 35 | 47 | 68 | 81 | 94 | 290 | 276 | 241 | 230 | 210 | 217 | |
| 9 | 9 | 9 | 9 | 21 | 21 | 93 | 88 | 58 | 57 | 51 | 48 | ||
| CWIP | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 17 | 26 | 38 | 47 | 60 | 73 | 198 | 188 | 183 | 172 | 160 | 169 | ||
| Total Assets | 26 | 35 | 47 | 68 | 81 | 94 | 290 | 276 | 241 | 230 | 210 | 217 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 2 | 3 | 1 | 7 | 5 | 25 | 26 | -9 | -0 | 11 | ||
| -2 | -3 | -3 | -13 | -1 | -2 | -44 | -9 | 20 | -2 | 1 | ||
| -1 | 2 | -0 | 13 | -4 | -4 | 20 | -17 | -10 | 2 | -12 | ||
| Net Cash Flow | -0 | 1 | -0 | 1 | 3 | -1 | 0 | -0 | -0 | -0 | 0 | |
| Free Cash Flow | 2 | 1 | 2 | -12 | 7 | 3 | -17 | 16 | 9 | -4 | 11 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 103% | 48% | 54% | 26% | 84% | 60% | 37% | 202% | 39% | -272% | 429% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 109 | 139 | 156 | 126 | 133 | 105 | 138 | 184 | 262 | 267 | |
| Inventory Days | 84 | 47 | 45 | 53 | 27 | 41 | 59 | 118 | 183 | 331 | 288 | |
| Days Payable | 130 | 133 | 163 | 154 | 91 | 106 | 113 | 165 | 254 | 405 | 317 | |
| Cash Conversion Cycle | 16 | 22 | 21 | 56 | 62 | 69 | 51 | 91 | 113 | 189 | 238 | |
| Working Capital Days | 19 | 10 | 14 | 48 | 40 | 53 | 20 | 24 | 58 | 72 | -8 | |
| ROCE % | 17% | 26% | 29% | 22% | 24% | 22% | 9% | 1% | -4% | -2% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export revenue (domiciled outside India) Rs Lakhs ・Standalone data |
|
|||||||||||
| Capacity Utilization of Dry Powder Vials % ・Standalone data |
||||||||||||
| Number of permanent employees count ・Standalone data |
||||||||||||
| Production volume of Dry Powder Vials Lakhs Pieces ・Standalone data |
||||||||||||
| Number of countries exporting to count ・Standalone data |
||||||||||||
| Order book position Rs crore ・Standalone data |
||||||||||||
| Revenue share - Government Institutions % of total revenue ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2026
- Q2FY27 results showed ₹266 lakh standalone loss; board appointed Preeti Sarin and auditors flagged debt/statutory defaults.
- Financial Results For The Quarter And Half Year Ended 30.09.2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Board approved Q2 and half-year FY2026 results; appointed Preeti Sarin as additional independent director for five years.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
- Board meeting on 14 November 2026 to approve Q2/H1 FY2026 unaudited financial results; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
Business Overview:[1][2][3]
ANGLIL is a part of the ANG Group which is a WHO-GMP–certified consortium of pharmaceutical companies. The company is engaged in the manufacturing of pharmaceuticals & allied products which include finished formulations in Non-Beta Lactam, Beta Lactam, Cephalosporin, and Carbapenem segments.